Is fertility sparing surgery a treatment option for premenopausal patients with dysgerminoma?

Iavazzo, Christos; Vorgias, George; Iavazzo, P; Gkegkes, Ioannis D.

doi:10.4149/bll_2016_131

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They primarily manifest in young and adolescent women with excellent prognosis if diagnosed in earlier stages [110]. These tumors are chemosensitive allowing fertility-sparing surgery in most cases [111]. A recent small cohort study reported a low mutational burden in OGCTs explaining their chemosensitive disposition [112].…”

Section: Ovarian Germ Cell Tumors (Ogcts)mentioning

confidence: 99%

Ovarian Cancer: Molecular Classification and Targeted Therapy

Ravindran¹,

Choudhary²

2021

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]

View full text Add to dashboard Cite

Ovarian cancer is the deadliest gynecological cancer among women with an overall 5-year survival rate below 50% due to its asymptomatic nature, diagnosis at advanced stages, and a high recurrence rate after standard therapy in 70% of cases. Ovarian cancers are heterogenous cancers where each subtype possesses a varied morphology and biologic behavior. Accumulating evidence has identified each of these subtypes characterized with specific pathways activated in each along with specific gene alterations. For example, high-grade serous ovarian cancer is characterized by universal TP53 mutation, mucinous ovarian cancer with KRAS mutation and clear cell or endometrioid ovarian cancers with ARID1A mutations. With the current focus of molecular-targeted therapies for cancer, such druggable markers serve as excellent targets for precision therapy and combination therapy. This chapter, provides an overview of the critical molecular pathways activated in the ovarian cancer subtypes with its druggable targets studied in ovarian cancer. We also highlight the implications of miRNAs in chemoresistance and sensitivity in the regulation of ovarian cancer.

show abstract

Section: Ovarian Germ Cell Tumors (Ogcts)mentioning

confidence: 99%

Ovarian Cancer: Molecular Classification and Targeted Therapy

Ravindran¹,

Choudhary²

2021

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]

View full text Add to dashboard Cite

show abstract

“…In Mexico, ovarian germ-cell tumors may represent up to 19% of total ovarian malignancies, with up to 59% diagnosed as dysgerminomas 5. Since dysgerminomas are more common in women of reproductive age, the standard treatment for dysgerminomas confined to the ovary is unilateral salpingo-oophorectomy to preserve fertility, followed by chemotherapy 6 7. Most patients with stage IA dysgerminoma are not treated with chemotherapy after the initial surgery, and tend to respond well to chemotherapy if relapse occurs 8.…”

Section: Introductionmentioning

confidence: 99%

Role of optimal cytoreduction in patients with dysgerminoma

Bandala-Jacques¹,

Estrada-Rivera²,

Cantú

et al. 2019

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

BackgroundDysgerminomas are malignant ovarian germ-cell tumors that typically affect young women. Although these tumors have an excellent response to chemotherapy, surgery is an integral part of primary treatment.ObjectiveTo evaluate outcomes of initial cytoreduction in patients diagnosed with dysgerminomas.MethodsPatients who underwent primary cytoreductive surgery for ovarian dysgerminoma between January 1985 and December 2013 were identified and included in the study. A comparison was made between patients who underwent optimal versus sub-optimal cytoreduction. Descriptive, comparative statistics and odds ratios were used to establish an association. Survival curves were performed with the Kaplan-Meier method and compared using a log-rank test. A value of p<0.05 was used to establish a statistical difference.ResultsA total of 180 patients with a histologically confirmed dysgerminoma were included in the analysis. A subsection of 37 patients in stages III/IV were analyzed. The median age at diagnosis was 21 years (IQR 18–26). Histologically, 166 (92.2%) patients had pure dysgerminomas, whereas the rest had mixed histologies. The median tumor size was 18 (IQR 12–22) cm. In all stages, factors associated with optimal cytoreduction, were higher lactate dehydrogenase levels (OR=1.01; p=0.03), higher CA125 levels (OR=1.01; p=0.04), receiving adjuvant chemotherapy (OR=0.22; p<0.01), or undergoing treatment in a specialized institution (OR=12.68; p<0.01). Patients in stages III/IV, initially managed outside our institution were less likely to be taken for cytoreduction (OR=16.88; p=0.013). Other factors, including age (OR=1.02; p=0.39), pelvic lymph-node positivity (OR=2.24; p=0.36), pregnancy during follow-up (OR=0.91: p=0.80), or recurrence of disease (OR=1.93; p=0.23) were found to be similar in both groups. Overall survival was higher in optimally cytoreducted patients (100% vs 95.7%; p=0.032) including all stages, but not if considering only stages III/IV (100% vs 90%, p=0.186); disease-free survival was the same for both groups regardless of stage (94.3% vs 91.1%; p=0.36).ConclusionPatients with optimal surgeries were most likely to be treated in referral centers. Initial residual disease did not significantly alter recurrence, progression, disease-free survival, or overall survival.

show abstract

Is fertility sparing surgery a treatment option for premenopausal patients with dysgerminoma?

Cited by 2 publications

References 17 publications

Ovarian Cancer: Molecular Classification and Targeted Therapy

Ovarian Cancer: Molecular Classification and Targeted Therapy

Role of optimal cytoreduction in patients with dysgerminoma

Contact Info

Product

Resources

About